Previous Article | Next Article 
Molecular and Cellular Biology, April 1999, p. 2754-2762, Vol. 19, No. 4
0270-7306/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Two Distinct Interleukin-3-Mediated Signal Pathways, Ras-NFIL3
(E4BP4) and Bcl-xL, Regulate the Survival of Murine
Pro-B Lymphocytes
Ryoko
Kuribara,1,2
Taisei
Kinoshita,3
Atsushi
Miyajima,3
Tetsuharu
Shinjyo,1
Takao
Yoshihara,4
Takeshi
Inukai,4
Keiya
Ozawa,1,2
A. Thomas
Look,4 and
Toshiya
Inaba1,*
Departments of Molecular
Biology1 and
Hematology,2 Jichi Medical School,
Tochigi 329-0498, and Institute of Molecular and Cellular
Bioscience, the University of Tokyo, Tokyo 174,3
Japan, and Department of Experimental Oncology, St. Jude
Children's Research Hospital, Memphis, Tennessee
381054
Received 15 July 1998/Returned for modification 6 September
1998/Accepted 22 January 1999
 |
ABSTRACT |
Hematopoietic cells require cytokine-initiated signals for survival
as well as proliferation. The pathways that transduce these signals,
ensuring timely regulation of cell fate genes, remain largely
undefined. The NFIL3 (E4BP4) transcription factor, Bcl-xL,
and constitutively active mutants of components in Ras signal
transduction pathways have been identified as key regulation proteins affecting murine interleukin-3 (IL-3)-dependent cell survival. Here we show that expression of NFIL3 is regulated by oncogenic Ras mutants through both the Raf-mitogen-activated protein kinase and phosphatidylinositol 3-kinase pathways. NFIL3 inhibits apoptosis without affecting Bcl-xL expression. By
contrast, Bcl-xL levels are regulated through the membrane
proximal portion in the cytoplasmic domain of the receptor
(
c chain), which is shared by IL-3 and granulocyte-macrophage
colony-stimulating factor. Activation of either pathway alone is
insufficient to ensure cell survival, indicating that
multiple independent signal transduction pathways mediate the survival
of developing B-lymphoid cells.
 |
INTRODUCTION |
Genes that regulate programmed cell
death are highly conserved among organisms as diverse as insects,
nematodes, and mammals. In the nematode Caenorhabditis
elegans, each cell death during development is controlled through
the coordinated action of three gene products, CED-3, CED-4, and
CED-9 (13), while in mammalian cells, this function is
performed by a group of CED-related proteins such as the caspases,
Apaf-1, and Bcl-2 family members (25, 29, 40). Indeed, the
activation of caspase-3 (CPP32) is essential for programmed cell death
induced by growth factor deprivation in several cytokine-dependent
hematopoietic cells, including murine interleukin-3 (IL-3)-dependent
cells such as Baf-3 pro-B lymphocytes (30). Moreover,
enforced expression of the IL-3-regulated Bcl-xL gene
protects Baf-3 cells from apoptosis caused by IL-3 depletion (27), suggesting that Bcl-xL regulation of
caspase-3 activity is a major mechanism contributing to programmed cell
death in this cell system.
Genetic programs controlling apoptosis also share upstream elements
that determine the fate of specific cell types. For instance, the
fates of the sister cells of specific neurons (NSM neurons) in C. elegans are regulated by two transcription factors, CES-1 and
CES-2 (12). CES-2 is a member of the basic region/leucine zipper (bZIP) transcription factor superfamily and is thought to act
through its consensus binding sequence to negatively regulate expression of the ces-1 gene, causing cells to undergo
apoptosis (28). Recently, we demonstrated that two
CES-2-related transcription factors, E2A-HLF and NFIL3 (also
called E4BP4), play critical roles in the regulation of apoptosis
in mammalian pro-B lymphocytes.
The E2A-HLF chimeric transcription factor is expressed by human
pro-B-cell leukemias harboring the t(17;19)(q22;p13) translocation (14, 17). In this chimera, the transactivation domain of E2A (also called E12/E47) is fused to the bZIP domain of hepatic leukemia factor, which has high homology with CES-2. E2A-HLF binds to the same
DNA sequence as does CES-2 and forms homodimers that trans activate gene expression (15, 17, 18, 20, 21). A
dominant-negative suppressor of E2A-HLF induces apoptotic cell
death in leukemic cells with the t(17;19) translocation. Moreover,
E2A-HLF markedly delays apoptosis caused by growth factor
deprivation in murine IL-3-dependent pro-B lymphocytes including Baf-3
and FL5.12 cells (19), suggesting that the chimeric protein
contributes to leukemogenesis by subverting the transcriptional
regulation system of programmed cell death in mammalian B-cell
precursors. Recently, we showed that a related bZIP protein, NFIL3
(also called E4BP4), is a cytokine-regulated mammalian transcription
factor highly homologous to CES-2 (16). Originally isolated
as a transcription factor binding to the adenovirus E4 promoter
sequence with trans-repressor activity (9), NFIL3 was later identified as a trans activator of IL-3 gene
expression in T cells (39). This protein also has a high
degree of homology with CES-2 and avidly binds to the same DNA sequence
recognized by CES-2 and E2A-HLF (9, 16). In Baf-3 and
FL5.12 cells, NFIL3 is a delayed early transcription factor induced by
IL-3 stimulation. Moreover, enforced expression of NFIL3 in FL5.12 cells delays apoptosis caused by IL-3 deprivation without
promoting cell division (16), indicating that induction of
NFIL3 is one of the mechanisms through which IL-3 suppresses apoptosis.
Previous studies have demonstrated that mutations leading to
constitutive Ras activation promote the development of
hematopoietic malignancies (reviewed in reference
22). We have also demonstrated that constitutively
active Ras proteins block apoptosis induced by IL-3 deprivation in
murine IL-3-dependent pro-B cells (33). Moreover, the
membrane distal region of the cytoplasmic domain of the signaling
receptor (common
chain or
c) shared by IL-3 and the
granulocyte-macrophage colony-stimulating factor (GM-CSF) is required
for both the survival and the activation of Ras in IL-3-dependent
hematopoietic cells (23). Most recently, we identified the
Raf-mitogen-activated protein kinase (MAPK) and
rapamycin-wortmannin-sensitive pathways (most likely
phosphatidylinositol 3-kinase [PI3-K] dependent) as pathways
downstream of oncogenic Ras in the prevention of apoptosis in
cytokine-deprived hematopoietic cells (24).
Here, we delineate two apparently independent pathways that
regulate apoptosis in cytokine-deprived Baf-3 cells. One emanates from
the membrane proximal portion of the
c chain and is involved in the
rapid regulation of Bcl-xL expression; the other involves the NFIL3 transcription factor downstream of oncogenic Ras mutants. These data indicate that multiple pathways are involved in the cytokine-mediated survival of pro-B lymphocytes.
 |
MATERIALS AND METHODS |
Cell culture and cell growth assay.
Mouse IL-3-dependent
Baf-3 pro-B lymphocytes were cultured in RPMI 1640 medium containing
10% fetal calf serum, 20 mM HEPES, 50 µM 2-mercaptoethanol, and
0.5% 10T1/2 conditioned medium as a source of murine IL-3. In some
experiments, recombinant mouse IL-3 (Wako Pure Chemicals, Osaka, Japan)
was used at concentrations described in the figure legends. Stable
transfectants of truncated forms of the human GM-CSF receptor and Ras
mutants were established in Baf-3 cells as described previously
(23, 33). Transfectants were maintained in medium containing
either 1 mg of G418 per ml of 200 µg of hygromycin per ml. To deplete
IL-3, cells were washed twice with either IL-3-free growth medium or
complete serum-free AIM-V medium (Gibco-BRL). Viable cell counts
were determined by trypan blue dye exclusion in triplicate assays.
BOSC23 cells, an ecotropic retrovirus packaging cell line, were
purchased from the American Type Culture Collection and cultured in
Dulbecco's modified Eagle's medium containing 10% fetal calf serum.
Retrovirus-mediated gene expression in Baf-3 cells.
To
construct a control CD8-expressing vector plasmid (pMX/IRES-CD8) for
retroviral gene transfer from the pMX retroviral vector (a gift of T. Kitamura) (31), we inserted an IRES-CD8 cassette in which
the mouse CD8 (lyt-2) cDNA was fused in frame to the internal ribosomal entry site sequence. Particular genes were expressed
by inserting their cDNAs immediately after the 5' long terminal repeat
sequence (Fig. 1A). The dominant-negative NFIL3 mutant contains a
defective NFIL3 basic domain characterized by substitution of nine of
the amino acid residues critical for DNA binding (YWEKRRKNNEAAKRSRE
mutated to YWEQSQQYSEPPQRSRE;
single-letter code). Retrovirus was made by the method of Kitamura and
coworkers (31) with minor modifications. Briefly, 3 × 106 BOSC23 cells were transfected with 6 µg of plasmid
vector DNA with Lipofectamine (Gibco-BRL) according to the
manufacturer's instructions. Two days later, 2 × 105
Baf-3 cells were infected with retrovirus by adding the conditioned medium from transfected BOSC23 cells. The infection was performed in
dishes coated with recombinant human fibronectin fragment (Retronectin; TaKaRa, Tokyo, Japan) at a concentration of 20 µg/cm2.
After 24 h, the cells were separated from the dish with cell dissociation buffer (Gibco-BRL) and transferred to a new flask. Cells
were cultured until the total number reached more than 3 × 106 (usually after 2 days), and the percentage of
CD8-positive cells was determined by flow cytometry to monitor
infection efficiency. CD8-positive cells were labeled with magnetic
microbeads conjugated with the CD8 monoclonal antibody and isolated on
MACS separation columns (Miltenyi Biotec, Gladbach, Germany) according
to the manufacturer's instructions. The selection procedure was
repeated until more than 95% of cells were shown to be positive for
CD8 by flow cytometry.
Electrophoretic mobility shift analysis.
Binding reactions
in the electrophoretic mobility shift assay (EMSA) were performed
by incubating 12 µg of nuclear protein lysate at 30°C for 15 min
with a 32P-end-labeled DNA oligonucleotide probe (2 × 104 cpm) containing the hepatic leukemia factor consensus
binding site sequence (5'-GCTACATATTACGTAACAAGCGTT-3')
in 12% glycerol-12 mM HEPES (pH 7.9)-4 mM Tris (pH
7.9)-133 mM KCl-1.5 µg of sheared calf thymus DNA-300 µg of
bovine serum albumin per ml as previously described (37).
Complexes were tested for binding to antisera by incubating 1 µl of
polyvalent immune rabbit antiserum to the nuclear protein lysates at
4°C for 30 min prior to the DNA binding reaction. Nondenaturing
polyacrylamide gels containing 4% acrylamide and 2.5% glycerol were
prerun at 4°C in a high-ionic-strength Tris-glycine buffer for 30 min
and run at 50 mA for approximately 45 min. The gel was then dried under
vacuum and analyzed by autoradiography.
Immunoblot analysis and antibodies.
Cells were solubilized
in Nonidet P-40 lysis buffer (150 mM NaCl, 1.0% Nonidet P-40, 50 mM
Tris, pH 8.0), and total cellular proteins were separated by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis. After wet
electrotransfer of the proteins onto polyvinylidene difluoride
membranes, proteins were detected by appropriate antibodies according
to standard procedures. The blots were then stained with primary
antibodies followed by horseradish peroxidase-conjugated anti-rabbit or
anti-mouse immunoglobulin secondary antibodies and subjected to
chemiluminescence detection according to the manufacturer's
instructions (Amersham). The following antibodies were used for
immunodetection. Anti-Bcl-x polyclonal antibodies were purchased from
Transduction Laboratories (Lexington, Ky.), anti-Bcl-2 (
C21) and
anti-c-Myc (N-262) antibodies were purchased from Santa Cruz
Biotechnology (Santa Cruz, Calif.), and anti-Akt and
anti-phosphorylated (Ser-473) Akt-specific antibodies were purchased
from New England BioLabs (Beverly, Mass.). Anti-NFIL3 antibodies were
previously described (16).
RNA extraction and Northern blot analysis.
Total cellular
RNA was isolated with the RNeasy kit according to the manufacturer's
instructions (Qiagen, Hilden, Germany). RNA samples (20 µg each) were
separated by electrophoresis in 1% agarose gels containing 2.2 M
formaldehyde, transferred to nylon membranes, and hybridized with
appropriate probes according to standard procedure.
 |
RESULTS |
NFIL3 delays apoptosis in Baf-3 cells deprived of IL-3.
Clonal variation and difficulties in isolating stable clones have
impeded studies in cytokine-dependent cells deprived of growth factors.
Thus, we established a retrovirus-mediated gene expression system that
allows mass transfer of genes followed by rapid selection without
prolonged culture in antibiotics (see Materials and Methods) (Fig.
1A). With this procedure, more than 95%
of infected Baf-3 cells expressed high levels of CD8 proved by flow
cytometry (data not shown). Immunoblot analysis documented protein
expression in these cells (Fig. 1B to E).

View larger version (28K):
[in this window]
[in a new window]
|
FIG. 1.
Schematic representation of retrovirus transduction
experiments. (A) Structure of the retroviral vector used in this study
(top); (ires, internal ribosomal entry site). Retrovirus-mediated gene
transfer was followed by cell selection with CD8 magnetic beads
(bottom) (also see Materials and Methods). LTR, long terminal repeat.
(B to E) Immunoblot analysis. Cell lysates from parental Baf-3 cells
(lanes 1 [B to E]) and cells infected with retrovirus expressing
Bcl-2 (B), Bcl-xL (C), c-Myc (D), and NFIL3 (E) (each in
lane 2) were analyzed with specific antibodies recognizing each
protein. (F) Parental Baf-3 cells and cells expressing CD8 only
(control), NFIL3, Bcl-2, c-Myc, or Bcl-xL were cultured in
IL-3-free medium; cell viability was determined at each time point by
trypan blue dye exclusion. Each value is the mean (± standard
deviation) of three independent experiments.
|
|
Removal of IL-3 from the culture medium induced apoptosis in
CD8-expressing Baf-3 cells, which died at essentially the same rate as
Baf-3 cells that did not receive the retrovirus (Fig. 1F). Cells
programmed to express Bcl-xL, Bcl-2, or NFIL3 were protected from apoptosis, with Bcl-xL exerting the most
profound antiapoptotic effect, while, as expected (3), those
expressing the c-Myc protein died more rapidly than controls. These
results indicate that, in addition to Bcl-2 family members, NFIL3 can inhibit apoptosis in IL-3-deprived Baf-3 cells in agreement with previous findings in FL5.12 cells (16).
Higher IL-3 concentrations are required for survival of
Baf-3 cells expressing a dominant-negative NFIL3
protein.
To confirm the antiapoptotic role of NFIL3 in
Baf-3 cells grown in IL-3-containing medium, we attempted
to suppress NFIL3 function by using a dominant-negative mutant
[NFIL3(dn)] containing a defective basic region but an intact
leucine zipper domain, which resulted in the formation of nonfunctional
heterodimers with wild-type NFIL3 (see Materials and Methods). By EMSA,
Baf-3 cells expressing NFIL3(dn) lacked functional NFIL3 protein
detectable with an oligonucleotide probe containing the NFIL3 binding
site (TTACGTAA) (Fig. 2A),
indicating that the mutant had suppressed DNA binding by NFIL3 in a
dominant-negative fashion. These cells required a 10-fold-greater
concentration of IL-3 to survive than did parental Baf-3 cells or
control CD8-expressing cells (Fig. 2B). The cell cycle distribution of
NFIL3(dn)-positive cells was unchanged as shown by flow cytometric
analysis (data not shown). Thus, the effect of NFIL3 on
cytokine-mediated cell survival was independent of an effect on cell
proliferation.

View larger version (19K):
[in this window]
[in a new window]
|
FIG. 2.
Baf-3 cells expressing dominant-negative NFIL3 require
higher concentrations of IL-3 to survive. (A) Antibody-perturbed EMSA
with lysates extracted from parental Baf-3 cells grown in 25 ng of IL-3
per ml (lane 1) and Baf-3 cells grown under the same conditions that
express the dominant-negative NFIL3 protein (lane 2). The reaction
mixture includes a 32P-labeled oligonucleotide probe
containing the NFIL3 binding sequence and anti-NFIL3 antiserum. The
arrowhead indicates a supershifted complex containing NFIL3. (B)
Parental Baf-3 cells and cells expressing the dominant-negative NFIL3
protein were cultured in serum-free AIM-V medium with recombinant
murine IL-3 at the indicated concentrations for 36 h, after which
the percentage of surviving cells was determined. Each value is the
mean (± standard deviation) of three independent experiments.
|
|
Oncogenic Ras induces NFIL3 expression.
We previously reported
that NFIL3 is an IL-3-responsive gene in Baf-3 cells
(16). Since pathways induced by oncogenic Ras are
required for the optimal survival of these cells (23, 24, 33), we considered that NFIL3 may be regulated through downstream pathways of oncogenic Ras mutants. To test this possibility, we used Baf-3 cells expressing a constitutively active Ras protein [Ras(G12V)] under the regulation of dexamethasone (Dex)
(23). When cells were cultured in IL-3-free medium for
8 h, the mRNA expression levels of endogenous NFIL3 were
down-regulated (lane 2, Fig. 3A). By
16 h after the addition of Dex, however, NFIL3 transcripts were
induced to levels similar to those induced by IL-3 (lane 6). In accord
with mRNA expression, NFIL3 protein expression was also induced by Dex
as shown by immunoblot analysis (Fig. 3B). EMSA revealed that NFIL3
protein bound to DNA recovered by 8 h after addition of Dex (Fig.
3C), when protein expression was barely detectable by immunoblot
analysis (Fig. 3B). This apparent discrepancy may be explained by the
different sensitivities of the two assays, because, in general, EMSA is
more sensitive than immunoblotting. In addition, alteration of the DNA
binding ability of NFIL3 may contribute to the discordance (see
Discussion). These effects appeared to be induced by Ras(G12V), not
by Dex itself, since neither mRNA nor protein expression of NFIL3 was
induced in wild-type Baf-3 cells after the addition of Dex (data
not shown), suggesting that the oncogenic Ras protein had induced NFIL3
expression.

View larger version (33K):
[in this window]
[in a new window]
|
FIG. 3.
Induction of NFIL3 by an oncogenic Ras mutant
[Ras(G12V)]. Baf-3 cells containing Dex-inducible
Ras(G12V) cDNA were cultured in IL-3-free medium. Dex
(10 7 M) was added to the culture medium 8 h after
IL-3 removal, and cells were cultured for the indicated period (hours).
(A) Northern blot analysis of total RNA. The blot was first hybridized
with a mouse NFIL3 cDNA probe and then rehybridized with a human
-actin probe. (B) Immunoblot analysis with whole-cell lysates. NFIL3
protein was detected with the polyclonal antibodies. (C)
Antibody-perturbed EMSA with nuclear extracts. The arrowhead indicates
a supershifted complex containing NFIL3.
|
|
Downstream pathways of Ras mediating NFIL3 expression.
To
identify downstream targets of Ras that could mediate NFIL3 expression
in Baf-3 cells, we tested NFIL3 induction by various Ras or Raf
mutants, which were shown to prevent apoptosis without obvious signs of
cell division in a previous study (33). The ability of these
mutants to prevent apoptosis and phosphorylate p42/MAPK, p70/S6 kinase,
and Akt is summarized in Table 1. Cells expressing the
Raf mutant (truncated N terminus), which
constitutively activates MAPK, were highly resistant to apoptosis. As
expected, the cells retained their capacity to express NFIL3 even when
cultured in IL-3-free medium (Fig. 4A,
lane 2), indicating that activation of the Raf-MAPK pathway is
sufficient for the induction of this transcription factor. In
experiments to test this hypothesis, the Ras(G12V/T35S) mutant,
which specifically but weakly activates the Raf-MAPK pathways
(2), had less ability than
Raf to induce NFIL3 (Fig. 4B,
lane 3) and only weakly influenced cell survival (Table 1). The
Ras(G12V/V45E) mutant, which activates S6K and Akt but not Raf-MAPK
pathways (34) (see also Fig. 8), prevented apoptosis
efficiently and induced appreciable levels of NFIL3 (Fig. 4C, lane 3),
suggesting that pathways downstream of Ras other than Raf-MAPK
pathways contribute to NFIL3 regulation. This interpretation was
confirmed by results with rapamycin, an inhibitor of the PI3-K-S6K
pathway (26, 36), which dramatically reduced the levels
of NFIL3 induced by Ras(G12V/V45E) (lane 4) and compromised cell
survival (Table 1). By contrast, substantial amounts of NFIL3 protein
were detected in Baf-3 cells expressing Ras(G12V) and cultured
in rapamycin-containing medium (Fig. 4D, lane 2), as would be expected
with the use of a reagent that does not affect the Raf-MAPK
pathways. In summary, the Ras-Raf and rapamycin-sensitive pathways independently induce NFIL3 expression, apparently through effects on the phosphorylation of p42/MAPK or p70/S6K.

View larger version (50K):
[in this window]
[in a new window]
|
FIG. 4.
Antibody-perturbed EMSA with nuclear lysates extracted
from Baf-3 cells expressing various mutants of Ras and Raf. (A)
Baf-3 cells expressing Raf were cultured in IL-3-containing
medium (lane 1) or IL-3-free medium for 18 h (lane 2). (B)
Baf-3 cells expressing Dex-regulated Ras(G12V/T35S) (lane 1)
were washed to remove IL-3 and then cultured in IL-3-free medium for
8 h (lane 2). Cells were then cultured in IL-3-free medium
containing 10 7 M Dex to induce Ras(G12V/T35S) for
another 18 h (lane 3). (C) Baf-3 cells expressing
Ras(G12V/V45E) were cultured in IL-3-containing medium (lane
1) and then washed to remove IL-3 and cultured in IL-3-free
medium for 8 h (lane 2). Cells were then cultured without (lane 3)
or with (lane 4) rapamycin (10 ng/ml) and maintained in IL-3-free
medium containing 10 7 M Dex to induce Ras(G12V/V45E).
(D) Baf-3 cells inducibly expressing Ras(G12V) were cultured in
IL-3-free medium for 8 h, then treated without (lane 1) or with
(lane 2) rapamycin (10 ng/ml), and then cultured in IL-3-free medium
containing 10 7 M Dex to induce Ras(G12V). Arrowheads
indicate supershifted DNA-protein complexes containing NFIL3.
|
|
Ras-independent pathways mediating NFIL3 expression.
To
further analyze pathways regulating the expression of NFIL3, we
used Baf-3 cells expressing the full-length or truncated form of
the
c human shared cytokine receptor chain. Because the membrane
distal region of the cytoplasmic
c chain activates Ras signaling
pathways,
544 cells that express the
c chain truncated at
amino acid 544 do not activate the Ras pathways after addition of
hGM-CSF to the culture medium (33). As controls, we used
455 cells expressing a
c chain lacking all of its cytoplasmic portion, as well as
c cells expressing the full-length
c chain.
As in an earlier study (23), the
c cells grew as well in
hGM-CSF-containing medium as in medium that contained IL-3, while the
455 cells could not divide and rapidly underwent apoptotic cell
death. The
544 cells proliferated well for approximately 60 h
with no evidence of loss of viability but thereafter underwent apoptosis at a rapid rate (Fig. 5A and
B). Flow cytometry
analysis with propidium iodide staining demonstrated that the
544
cells had accumulated in G0/G1 phase prior to
the onset of apoptosis at 60 h following the addition of hGM-CSF
(data not shown).

View larger version (25K):
[in this window]
[in a new window]
|
FIG. 5.
Ras-independent pathways also mediate NFIL3
expression. (A and B) 544 cells, 544 cells expressing NFIL3, and
544 cells expressing CD8 as a control were cultured in cytokine-free
medium for 8 h ( 8 to 0); then hGM-CSF was added to the medium at
a concentration of 5 ng/ml. Cell number (A) and percent viability (B)
were determined by trypan blue dye exclusion. A representative
experiment is shown; similar results were obtained in two other
independent experiments. (C and D) EMSA with nuclear lysates extracted
from c or 455 (C) or 544 (D) cells expressing the full-length or
a truncated form of the human common chain. Cells were cultured in
cytokine-free medium for 8 h ( 8 to 0); then hGM-CSF was added to
the medium at a concentration of 5 ng/ml, and the cells were cultured
for the indicated period (hours). Open arrowheads indicate supershifted
DNA-protein complexes containing NFIL3.
|
|
hGM-CSF induced NFIL3 expression in
c cells but not in
455
cells (Fig. 5C). In
544 cells exposed to hGM-CSF, NFIL3 expression was transient and much less pronounced than in
c cells (Fig. 5D), suggesting that Ras is required for the stable expression of
NFIL3. Interestingly, as long as
544 cells expressed NFIL3, they
remained alive, but when NFIL3 began to fall, the cells underwent apoptosis. To confirm the apparent role of NFIL3 in the survival of
these cells, we infected
544 cells with a retrovirus made from the
pMX-NFIL3/IRES-CD8 vector and selected CD8-positive cells. As
demonstrated in Fig. 5A and B,
544 cells constitutively expressing NFIL3 were more resistant to apoptosis, indicating that NFIL3 at least
partially substitutes for Ras signals in preventing the suicide. These
results therefore suggest a role for Ras-mediated pathways in the
maintenance of both NFIL3 levels and cell survival in response to cytokines.
Induction of Bcl-xL by oncogenic Ras.
Cell
survival signals originating from cytokine receptors also regulate
proteins involved in the general apoptosis program, including members
of the Bcl-2 and caspase families. In fact, we previously reported that
caspase-3 activity is elevated in cytokine-dependent cells that undergo
apoptosis caused by cytokine deprivation (30). Because
caspase activity is regulated by some of the Bcl-2 family members, we
compared expression levels of the members of the Bcl-2 family
(Bcl-2, Bcl-xL, Bax, Bad, and Bak) in Baf-3 cells
cultured in medium with or without IL-3. The results indicated that, of
the proteins analyzed, only Bcl-xL (mRNA and protein)
was regulated by IL-3 (Fig. 6A and
7A), in agreement with findings of
Leverrier et al. (27). Moreover, enforced expression of this
protein protected cells from apoptosis caused by IL-3 starvation (Fig.
1F), underscoring its major role in the general apoptosis program
regulating the cytokine-mediated survival of Baf-3 cells.

View larger version (37K):
[in this window]
[in a new window]
|
FIG. 6.
Bcl-xL mRNA expression in Baf-3 cells.
The blots were first hybridized with a mouse Bcl-x cDNA probe and then
rehybridized with a human -actin probe. (A) Parental Baf-3 cells
were cultured in IL-3-free medium for the indicated periods. (B and C)
Baf-3 cells containing Dex-inducible Ras(G12V) (B) or
Ras(G12V/V45E) (C) were cultured in medium containing
10 7 M Dex for 16 h; the cells were then cultured in
IL-3-free, Dex-containing medium for the indicated period. (D)
Baf-3 cells containing Dex-inducible Ras(G12V/V45E) were
cultured in medium containing 10 7 M Dex for 16 h;
the cells were then cultured in IL-3-free, Dex-containing medium with
100 nM wortmannin for the indicated period.
|
|

View larger version (24K):
[in this window]
[in a new window]
|
FIG. 7.
Expression of Bcl-xL protein in Baf-3
cells. (A) Parental Baf-3 cells were cultured in IL-3-free medium
for the indicated periods. (B and C) Baf-3 cells containing
Dex-inducible Ras(G12V) (B) or Ras(G12V/V45E) (C) were cultured
in medium containing 10 7 M Dex for 16 h; the cells
were then cultured in IL-3-free, Dex-containing medium for the
indicated period. (D) Baf-3 cells containing Dex-inducible
Ras(G12V/V45E) were cultured in medium containing 10 7
M Dex for 16 h; the cells were then cultured in IL-3-free,
Dex-containing medium with 100 nM wortmannin for the indicated
period.
|
|
To determine whether oncogenic Ras blocks apoptosis through
Bcl-xL gene regulation, we performed Northern
blot and immunoblot analysis with RNA and total cell lysates
extracted from Baf-3 cells expressing the Ras(G12V) mutant.
Bcl-xL mRNA and protein levels were down-regulated in
IL-3-deprived Baf-3 cells expressing the oncogenic Ras mutant, as
previously observed in parental Baf-3 cells, with a return to
baseline levels by 24 h (Fig. 6B and 7B). Both Ras(G12V/V45E)
and
Raf induced Bcl-xL expression in the same
manner as Ras(G12V) did (Fig. 6C and 7C and data not shown), indicating that both the Ras-PI3-K and Raf-MAPK pathways are
involved in the slow induction of Bcl-xL.
Since involvement of the PI3-K-Akt pathways in cytokine-mediated
cell survival has been reported recently (1, 35), we used
wortmannin to test whether the pathways contribute to inhibition of
apoptosis through induction of Bcl-xL. Baf-3 cells
expressing Ras(G12V) or Ras(G12V/V45E) by Dex were cultured
without IL-3. As we previously reported (24), cells
expressing Ras(G12V/V45E), but not those expressing
Ras(G12V), underwent apoptosis by addition of 100 nM
wortmannin in culture medium (Table 1), suggesting that signals
mediated by the Ras-PI3-K pathways play central roles in
inhibiting apoptosis in cells expressing Ras(G12V/V45E) cultured in
IL-3-free medium. As expected, levels of phosphorylated Akt were
down-regulated by the treatment of wortmannin (Fig.
8). However, expression levels of
Bcl-xL mRNA and protein were not affected (Fig. 6D and 7D),
suggesting that signals mediated by the PI3-K-Akt pathways protect
cells from apoptosis through mechanisms independent of
Bcl-xL.

View larger version (58K):
[in this window]
[in a new window]
|
FIG. 8.
Expression and phosphorylation of Akt in Baf-3 cells
expressing Ras(G12V/V45E). Baf-3 cells containing Dex-inducible
Ras(G12V/V45E) were cultured in IL-3-containing medium without Dex
(lane 1) or with 10 7 M Dex for 16 h (lane 2). The
Dex-treated cells were then cultured in IL-3-free, Dex-containing
medium for 12 h without wortmannin (lane 3) or with 100 nM
wortmannin (lane 4). Phosphorylated Akt at Ser-473 (upper panel) or
total Akt (lower panel) protein was detected with antibodies specific
for each protein.
|
|
Ras-independent induction of Bcl-xL.
The results
described above raised the possibility that the regulation of the
Bcl-xL gene expression involves Ras-independent pathways. To test the possibility, we cultured
544 cells in
hGM-CSF-containing medium, which does not activate the Ras
pathways, and analyzed the expression of Bcl-xL.
Bcl-xL mRNA was barely detectable 8 h after IL-3
removal, returning rapidly to its original level after the addition of
hGM-CSF (Fig. 9A). Moreover,
Bcl-xL protein levels were maintained for more than 63 h (Fig. 9B), when the cells underwent apoptosis (Fig. 5B), indicating
that Ras-independent pathways can induce the expression of
Bcl-xL but are unable to maintain the survival of Baf-3
cells.

View larger version (48K):
[in this window]
[in a new window]
|
FIG. 9.
Expression of Bcl-xL mRNA (A and C) and
protein (B and D) in Baf-3 cells. The Northern blots were first
hybridized with a mouse Bcl-x cDNA probe and then rehybridized with a
human -actin probe. (A and B) 544 cells were cultured in medium
lacking either IL-3 or hGM-CSF for 8 h (lanes 2). Then cells were
cultured in medium containing hGM-CSF for the indicated periods. (C and
D) Baf-3 cells expressing NFIL3 were cultured in IL-3-free medium
for the indicated periods.
|
|
We next tested whether NFIL3 induces expression of Bcl-xL.
Baf-3 cells expressing NFIL3 were deprived of IL-3, and total RNA and cell lysates were extracted. Northern blot and immunoblot analysis
revealed that both mRNA and protein expression of Bcl-xL were quickly down-regulated by IL-3 starvation (Fig. 9C and D), suggesting that NFIL3 delays apoptosis through mechanisms other than
the induction of Bcl-xL.
 |
DISCUSSION |
In earlier studies, we established that constitutively active Ras
proteins and NFIL3 block apoptosis in cytokine-starved murine IL-3-dependent pro-B lymphocytes (16, 23, 24). We and others also demonstrated that the general cell death machinery, including Bcl-xL and caspase-3, ultimately controls the death of
cytokine-deprived Baf-3 lymphocytes (27, 30), but the
pathways regulating the expression and activity of these proteins
remained unclear. Here we describe two distinct signaling pathways
that appear to regulate cell survival (summarized in Fig.
10); one originates from the membrane
proximal portion of the
c chain and is involved in the rapid and
stable regulation of Bcl-xL, while the other pathway involves the NFIL3 transcription factor downstream of oncogenic Ras
proteins.

View larger version (19K):
[in this window]
[in a new window]
|
FIG. 10.
Proposed signaling pathways regulating cell
survival in Baf-3 cells that originate from segments of the
cytokine-activated c chain and proceed to the general apoptosis
program through the signal transduction and transcriptional regulatory
system. Signals arising from the membrane proximal portion of the c
chain contribute to the rapid and stable expression of
Bcl-xL but induce NFIL3 only transiently (lightly dashed
line). By contrast, signals from the membrane distal domain of the c
chain activate Ras-mediated pathways. A constitutively active Ras
protein [Ras(G12V)] regulates the stable expression of the NFIL3
transcription factor through both the Raf-MAPK and PI3-K pathways.
Oncogenic Ras is also involved in the slow but stable induction of
Bcl-xL (heavily dashed line).
|
|
Signals originating from the membrane proximal domain of the
c chain
likely regulate the expression of Bcl-xL, as shown by experiments using
544 cells stimulated with hGM-CSF, in which Bcl-xL expression levels were demonstrated to be similar
to those in Baf-3 cells cultured with IL-3 (Fig. 9A and B).
Oncogenic Ras did not block the rapid decline of
Bcl-xL mRNA and protein levels after IL-3
deprivation. In addition, wortmannin-sensitive pathways including
pathways involving PI3-K and Akt did not regulate
Bcl-xL expression (Fig. 6 and 7). These data agree with the
results of experiments by Packham et al. using the 32D, IL-3-dependent
murine myeloid cell line, which indicate that the regulation of
Bcl-xL protein levels is mediated by the Jak kinase
pathway and is independent of other signaling effectors including
PI3-K and Ras (32). Nevertheless,
544 cells cultured with
hGM-CSF underwent apoptosis, indicating that signals from the membrane
distal domain of the
c chain are also required to protect cells from
apoptosis. Because Ras is activated through signals mediated by the
c chain distal portion, and because an oncogenic Ras mutant
[Ras(G12V)] rescued
544 cells from apoptosis completely
(23), it appears likely that one or more genes downstream of
Ras(G12V) are required for cell survival in addition to
Bcl-xL. NFIL3 appears to be a signaling component in
Ras-mediated survival pathways, because this transcription factor
is induced by IL-3 (16) and Ras(G12V) (Fig. 3) in
Baf-3 cells, but only transiently by hGM-CSF in
544 cells (Fig. 5D), and the enforced expression of NFIL3 in
544
cells delays apoptosis (Fig. 5A and B).
We previously reported that DNA binding ability, as well as the
expression levels of NFIL3, is regulated by IL-3 (16). DNA binding of this transcription factor may also be up-regulated by
Ras-mediated signals (Fig. 3B and C). Evidence has been published that
in vitro-phosphorylated NFIL3 is able to bind its consensus sequence
more avidly than nonphosphorylated protein (5). Thus, oncogenic Ras may regulate NFIL3 not only by up-regulating its expression levels but also through posttranslational effects on DNA binding.
The incomplete ability of NFIL3 to rescue
544 cells cultured in
medium containing hGM-CSF indicates that this transcription factor is not the only downstream target of Ras(G12V) that is required to prevent cell death. Candidates for additional components of
Ras-mediated survival pathways include other transcription factors,
members of the antiapoptotic Bcl-2 superfamily, or members of the
BH3 domain-containing group of cell death activators, such as Bad, Bax,
Bak, etc. Recently, IL-3-dependent phosphorylation of Bad
overexpressed in FL5.12 cells was reported to mediate cell survival
(38). Moreover, Bad phosphorylation in this cell system is
mediated at least in part by Akt, which is downstream of PI3-K (10, 11). However, because endogenous Bad proteins in
Baf-3 cells cultured in IL-3-containing medium are not
phosphorylated at detectable levels (data not shown), it is difficult
to evaluate the importance of this mechanism.
The downstream factors through which NFIL3 delays apoptosis in
IL-3-deprived Baf-3 cells have as yet not been identified. One
possibility is that NFIL3 induces the expression of cytokines in
Baf-3 cells and blocks apoptosis through an autocrine mechanism, because this transcription factor has been reported to trans
activate the IL-3 promoter in T cells (39). However, we have
been unable to detect the IL-3 mRNA or protein in Baf-3 cells
overexpressing NFIL3 and in conditioned medium from these cells
(16), although the involvement of another cytokine(s) has
not been ruled out. Another possibility is that NFIL3 induces
antiapoptotic Bcl-2 family members; however, we have not been able to
detect the induction of a known antiapoptotic Bcl-2 family member (Fig.
9C and D and data not shown). Recent findings on the regulation of
programmed cell death in C. elegans may provide insight into
this issue. The EGL-1 protein, which was recently identified as an
upstream component of the general cell death machinery in the worm,
contains a Bcl-2 homology region 3 (BH3)-like domain but does not
contain a BH1, BH2, or BH4 domain (6). EGL-1 directly binds
to CED-9 and is considered to inhibit its function. Because Egl-1
likely acts downstream of CES-1 and CES-2 (6), mammalian
members of the BH3-only-containing group of cell death activators, such
as Bid, Bik, or Hrk, would appear to be candidate target proteins of NFIL3.
Factors involved in the control of apoptosis have been implicated in
oncogenic signaling cascades. NFIL3, for example, may act in some cells
as a physiological counterpart of the leukemogenic E2A-HLF
fusion transcription factor (16), by transmitting
survival signals emanating from oncogenic Ras proteins. Ras
pathways are activated in leukemogenesis not only by
activating point mutations, but also by loss-of-function mutations of
the NF1 tumor suppressor gene in juvenile-type chronic
myelogenous leukemia (4). In addition, the BCR-ABL chimeric
tyrosine kinase, implicated in the pathogenesis of Philadelphia
chromosome-positive leukemias, acts in part through Ras-mediated
signals (7, 8). Not surprisingly, we have shown that NFIL3
expression is induced by the BCR-ABL chimera in Baf-3 cells (data
not shown), suggesting that Ras-NFIL3 pathways may be common
targets for a variety of oncogenes. The dissection of transcriptional
networks through which NFIL3 affects cell survival may ultimately
provide insight into the role of Ras gene activation and its
contribution to malignant transformation.
 |
ACKNOWLEDGMENTS |
We are indebted to T. Kitamura for providing the pMX retrovirus
vector, John Gilbert for editorial review, and John L. Cleveland for
critical comments.
This research was supported by grants-in-aid from the Ministry of
Education, Science and Culture of Japan; by the Senri Life Science
Foundation; by grants from the National Cancer Institute (CA 59571 and
Cancer Center Core CA 21765); and by the American Lebanese Syrian
Associated Charities (ALSAC), St. Jude Children's Research Hospital.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Molecular Biology, Jichi Medical School, 3311-1 Yakushiji,
Minamikawachi-machi, Tochigi 329-0498, Japan. Phone: 81-285-58-7402. Fax: 81-285-44-8675. E-mail: tinaba{at}jichi.ac.jp.
 |
REFERENCES |
| 1.
|
Ahmed, N. N.,
H. L. Grimes,
A. Bellacosa,
T. O. Chan, and P. N. Tsichlis.
1997.
Transduction of interleukin-2 antiapoptotic and proliferative signals via Akt protein kinase.
Proc. Natl. Acad. Sci. USA
94:3627-3632[Abstract/Free Full Text].
|
| 2.
|
Akasaka, K.,
M. Tamada,
F. Wang,
K. Kariya,
F. Shima,
A. Kikuchi,
M. Yamamoto,
M. Shirouzu,
S. Yokoyama, and T. Kataoka.
1996.
Differential structural requirements for interaction of Ras protein with its distinct downstream effectors.
J. Biol. Chem.
271:5353-5360[Abstract/Free Full Text].
|
| 3.
|
Askew, D. S.,
R. A. Ashmun,
B. C. Simmons, and J. L. Cleveland.
1991.
Constitutive c-myc expression in an IL-3-dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis.
Oncogene
6:1915-1922[Medline].
|
| 4.
|
Bollag, G.,
D. W. Clapp,
S. Shih,
F. Adler,
Y. Y. Zhang,
P. Thompson,
B. J. Lange,
M. H. Freedman,
F. McCormick,
T. Jacks, and K. Shannon.
1996.
Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells.
Nat. Genet.
12:144-148[Medline].
|
| 5.
|
Chen, W.-J.,
K. S. Lewis,
G. Chandra,
J. P. Cogswell,
S. W. Stinnett,
S. H. Kadwell, and J. G. Gray.
1995.
Characterization of human E4BP4, a phosphorylated bZIP factor.
Biochim. Biophys. Acta
1264:388-396[Medline].
|
| 6.
|
Conradt, B., and H. R. Horvitz.
1998.
The C. elegans protein EGL-1 is required for programmed cell death and interacts with the Bcl-2-like protein CED-9.
Cell
93:519-529[Medline].
|
| 7.
|
Cortez, D.,
L. Kadlec, and A. M. Pendergast.
1995.
Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis.
Mol. Cell. Biol.
15:5531-5541[Abstract].
|
| 8.
|
Cortez, D.,
G. Stoica,
J. H. Pierce, and A. M. Pendergast.
1996.
The BCR-ABL tyrosine kinase inhibits apoptosis by activating a Ras-dependent signaling pathway.
Oncogene
13:2589-2594[Medline].
|
| 9.
|
Cowell, I. G.,
A. Skinner, and H. C. Hurst.
1992.
Transcriptional repression by a novel member of the bZIP family of transcription factors.
Mol. Cell. Biol.
12:3070-3077[Abstract/Free Full Text].
|
| 10.
|
Datta, S. R.,
H. Dudek,
X. Tao,
S. Masters,
H. Fu,
Y. Gotoh, and M. E. Greenberg.
1997.
Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery.
Cell
91:231-241[Medline].
|
| 11.
|
del Peso, L.,
M. Gonzalez-Garcia,
C. Page,
R. Herrera, and G. Nunez.
1997.
Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt.
Science
278:687-689[Abstract/Free Full Text].
|
| 12.
|
Ellis, R. E., and H. R. Horvitz.
1991.
Two C. elegans genes control the programmed deaths of specific cells in the pharynx.
Development
112:591-603[Abstract].
|
| 13.
|
Ellis, R. E.,
J. Y. Yuan, and H. R. Horvitz.
1991.
Mechanisms and functions of cell death.
Annu. Rev. Cell Biol.
7:663-698.
|
| 14.
|
Hunger, S. P.,
K. Ohyashiki,
K. Toyama, and M. L. Cleary.
1992.
HLF, a novel hepatic bZIP protein, shows altered DNA-binding properties following fusion to E2A in t(17;19) acute lymphoblastic leukemia.
Genes Dev.
6:1608-1620[Abstract/Free Full Text].
|
| 15.
|
Hunger, S. P.,
R. Brown, and M. L. Cleary.
1994.
DNA-binding and transcriptional regulatory properties of hepatic leukemia factor (HLF) and the t(17;19) acute lymphoblastic leukemia chimera E2A-HLF.
Mol. Cell. Biol.
14:5986-5996[Abstract/Free Full Text].
|
| 16.
|
Ikushima, S.,
T. Inukai,
T. Inaba,
S. D. Nimer,
J. L. Cleveland, and A. T. Look.
1997.
Pivotal role for the NFIL3/E4BP4 transcription factor in IL-3-mediated survival of pro-B lymphocytes.
Proc. Natl. Acad. Sci. USA
94:2609-2614[Abstract/Free Full Text].
|
| 17.
|
Inaba, T.,
W. M. Roberts,
L. H. Shapiro,
K. W. Jolly,
S. C. Raimondi,
S. D. Smith, and A. T. Look.
1992.
Fusion of the leucine zipper gene HLF to the E2A gene in human acute B-lineage leukemia.
Science
257:531-534[Abstract/Free Full Text].
|
| 18.
|
Inaba, T.,
L. H. Shapiro,
T. Funabiki,
A. E. Sinclair,
B. G. Jones,
R. A. Ashmun, and A. T. Look.
1994.
DNA-binding specificity and trans-activating potential of the leukemia-associated E2A-hepatic leukemia factor fusion protein.
Mol. Cell. Biol.
14:3403-3413[Abstract/Free Full Text].
|
| 19.
|
Inaba, T.,
T. Inukai,
T. Yoshihara,
H. Seyschab,
R. A. Ashmun,
C. E. Canman,
S. J. Laken,
M. B. Kastan, and A. T. Look.
1996.
Reversal of apoptosis by the leukemia-associated E2A-HLF chimeric transcription factor.
Nature
382:541-544[Medline].
|
| 20.
|
Inukai, T.,
T. Inaba,
T. Yoshihara, and A. T. Look.
1997.
Cell transformation mediated by homodimeric E2A-HLF transcription factors.
Mol. Cell. Biol.
17:1417-1424[Abstract].
|
| 21.
|
Inukai, T.,
T. Inaba,
S. Ikushima, and A. T. Look.
1998.
The AD1 and AD2 transactivation domains of E2A are essential for the antiapoptotic activity of the E2A-HLF chimeric oncoprotein.
Mol. Cell. Biol.
18:6035-6043[Abstract/Free Full Text].
|
| 22.
|
Joneson, T., and D. Bar Sagi.
1997.
Ras effectors and their role in mitogenesis and oncogenesis.
J. Mol. Med.
75:587-593[Medline].
|
| 23.
|
Kinoshita, T.,
T. Yokota,
K. Arai, and A. Miyajima.
1995.
Suppression of apoptotic death in hematopoietic cells by signaling through the IL-3/GM-CSF receptors.
EMBO J.
14:266-275[Medline].
|
| 24.
|
Kinoshita, T.,
M. Shirouzu,
A. Kamiya,
K. Hashimoto,
S. Yokoyama, and A. Miyajima.
1997.
Raf/MAPK and rapamycin-sensitive pathways mediate the anti-apoptotic function of p21Ras in IL-3-dependent hematopoietic cells.
Oncogene
15:619-627[Medline].
|
| 25.
|
Kroemer, G.
1997.
The proto-oncogene Bcl-2 and its role in regulating apoptosis.
Nat. Med.
3:614-620[Medline].
|
| 26.
|
Kuo, C. J.,
J. Chung,
D. F. Fiorentino,
W. M. Flanagan,
J. Blenis, and G. R. Crabtree.
1992.
Rapamycin selectively inhibits interleukin-2 activation of p70 S6 kinase.
Nature
358:70-73[Medline].
|
| 27.
|
Leverrier, Y.,
J. Thomas,
G. R. Perkins,
M. Mangeney,
M. K. L. Collins, and J. Marvel.
1997.
In bone marrow derived Baf-3 cells, inhibition of apoptosis by IL-3 is mediated by two independent pathways.
Oncogene
14:425-430[Medline].
|
| 28.
|
Metzstein, M. M.,
M. O. Hengartner,
N. Tsung,
R. E. Ellis, and H. R. Horvitz.
1996.
Transcriptional regulator of programmed cell death encoded by Caenorhabditis elegans gene ces-2.
Nature
382:545-547[Medline].
|
| 29.
|
Nicholson, D. W., and N. A. Thornberry.
1997.
Caspases: killer proteases.
Trends Biochem. Sci.
22:299-306[Medline].
|
| 30.
|
Ohta, T.,
T. Kinoshita,
M. Naito,
T. Nozaki,
M. Masutani,
T. Tsuruo, and A. Miyajima.
1997.
Requirement of the caspase-3/CPP32 protease cascade for apoptotic death following cytokine deprivation in hematopoietic cells.
J. Biol. Chem.
272:23111-23116[Abstract/Free Full Text].
|
| 31.
|
Onishi, M.,
S. Kinoshita,
Y. Morikawa,
A. Shibuya,
J. Phillips,
L. L. Lanier,
D. M. Gorman,
G. P. Nolan,
A. Miyajima, and T. Kitamura.
1996.
Application of retrovirus-mediated expression cloning.
Exp. Hematol.
24:324-329[Medline].
|
| 32.
|
Packham, G.,
E. L. White,
C. M. Eischen,
H. Yang,
E. Parganas,
J. N. Ihle,
D. A. Grillot,
G. P. Zambetti,
G. Nunez, and J. L. Cleveland.
1998.
Selective regulation of Bcl-XL by a Jak kinase-dependent pathway is bypassed in murine hematopoietic malignancies.
Genes Dev.
12:2475-2487[Abstract/Free Full Text].
|
| 33.
|
Sato, N.,
K. Sakamaki,
N. Terada,
K. Arai, and A. Miyajima.
1993.
Signal transduction by the high-affinity GM-CSF receptor: two distinct cytoplasmic regions of the common subunit responsible for different signaling.
EMBO J.
12:4181-4189[Medline].
|
| 34.
|
Shirouzu, M.,
H. Koide,
Y.-J. Fujita,
H. Oshio,
Y. Toyama,
K. Yamasaki,
S. A. Fuhrman,
E. Villafranca,
Y. Kaziro, and S. Yokoyama.
1994.
Mutations that abolish the ability of Ha-Ras to associate with Raf-1.
Oncogene
9:2153-2157[Medline].
|
| 35.
|
Songyang, Z.,
D. Baltimore,
L. C. Cantley,
D. R. Kaplan, and T. F. Franke.
1997.
Interleukin 3-dependent survival by the Akt protein kinase.
Proc. Natl. Acad. Sci. USA
94:11345-11350[Abstract/Free Full Text].
|
| 36.
|
Terada, N.,
J. J. Lucas,
A. Szepesi,
R. A. Franklin,
K. Takase, and E. W. Gelfand.
1992.
Rapamycin inhibits the phosphorylation of p70 S6 kinase in IL-2 and mitogen-activated human T cells.
Biochem. Biophys. Res. Commun.
186:1315-1321[Medline].
|
| 37.
|
Yoshihara, T.,
T. Inaba,
L. H. Shapiro,
J. Kato, and A. T. Look.
1995.
E2A-HLF-mediated cell transformation requires both the trans-activation domains of E2A and the leucine zipper dimerization domain of HLF.
Mol. Cell. Biol.
15:3247-3255[Abstract].
|
| 38.
|
Zha, J.,
H. Harada,
E. Yang,
J. Jockel, and S. J. Korsmeyer.
1996.
Serine phosphorylation of death agonist Bad in response to survival factor results in binding to 14-3-3 not Bcl-xL.
Cell
87:619-628[Medline].
|
| 39.
|
Zhang, W.,
J. Zhang,
M. Kornuc,
K. Kwan,
R. Frank, and S. D. Nimer.
1995.
Molecular cloning and characterization of NF-IL3A, a transcriptional activator of the human interleukin-3 promoter.
Mol. Cell. Biol.
15:6055-6063[Abstract].
|
| 40.
|
Zou, H.,
W. J. Henzel,
X. Liu,
A. Lutschg, and X. Wang.
1997.
Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3.
Cell
90:405-413[Medline].
|
Molecular and Cellular Biology, April 1999, p. 2754-2762, Vol. 19, No. 4
0270-7306/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Alvarez, J. V., Febbo, P. G., Ramaswamy, S., Loda, M., Richardson, A., Frank, D. A.
(2005). Identification of a Genetic Signature of Activated Signal Transducer and Activator of Transcription 3 in Human Tumors. Cancer Res.
65: 5054-5062
[Abstract]
[Full Text]
-
Inukai, T., Inaba, T., Dang, J., Kuribara, R., Ozawa, K., Miyajima, A., Wu, W., Look, A. T., Arinobu, Y., Iwasaki, H., Akashi, K., Kagami, K., Goi, K., Sugita, K., Nakazawa, S.
(2005). TEF, an antiapoptotic bZIP transcription factor related to the oncogenic E2A-HLF chimera, inhibits cell growth by down-regulating expression of the common {beta} chain of cytokine receptors. Blood
105: 4437-4444
[Abstract]
[Full Text]
-
Peeters, P. J., Gohlmann, H. W., Van den Wyngaert, I., Swagemakers, S. M., Bijnens, L., Kass, S. U., Steckler, T.
(2004). Transcriptional Response to Corticotropin-Releasing Factor in AtT-20 Cells. Mol. Pharmacol.
66: 1083-1092
[Abstract]
[Full Text]
-
Greenbaum, S., Lazorchak, A. S., Zhuang, Y.
(2004). Differential Functions for the Transcription Factor E2A in Positive and Negative Gene Regulation in Pre-B Lymphocytes. J. Biol. Chem.
279: 45028-45035
[Abstract]
[Full Text]
-
Junghans, D., Chauvet, S., Buhler, E., Dudley, K., Sykes, T., Henderson, C. E.
(2004). The CES-2-related transcription factor E4BP4 is an intrinsic regulator of motoneuron growth and survival. Development
131: 4425-4434
[Abstract]
[Full Text]
-
Ozkurt, I. C., Pirih, F. Q., Tetradis, S.
(2004). Parathyroid Hormone Induces E4bp4 Messenger Ribonucleic Acid Expression Primarily through Cyclic Adenosine 3',5'-Monophosphate Signaling in Osteoblasts. Endocrinology
145: 3696-3703
[Abstract]
[Full Text]
-
Kuribara, R., Honda, H., Matsui, H., Shinjyo, T., Inukai, T., Sugita, K., Nakazawa, S., Hirai, H., Ozawa, K., Inaba, T.
(2004). Roles of Bim in Apoptosis of Normal and Bcr-Abl-Expressing Hematopoietic Progenitors. Mol. Cell. Biol.
24: 6172-6183
[Abstract]
[Full Text]
-
Matsunaga, T., Inaba, T., Matsui, H., Okuya, M., Miyajima, A., Inukai, T., Funabiki, T., Endo, M., Look, A. T., Kurosawa, H.
(2004). Regulation of annexin II by cytokine-initiated signaling pathways and E2A-HLF oncoprotein. Blood
103: 3185-3191
[Abstract]
[Full Text]
-
Guthridge, M. A., Barry, E. F., Felquer, F. A., McClure, B. J., Stomski, F. C., Ramshaw, H., Lopez, A. F.
(2004). The phosphoserine-585-dependent pathway of the GM-CSF/IL-3/IL-5 receptors mediates hematopoietic cell survival through activation of NF-{kappa}B and induction of bcl-2. Blood
103: 820-827
[Abstract]
[Full Text]
-
Lund, R., Aittokallio, T., Nevalainen, O., Lahesmaa, R.
(2003). Identification of Novel Genes Regulated by IL-12, IL-4, or TGF-{beta} during the Early Polarization of CD4+ Lymphocytes. J. Immunol.
171: 5328-5336
[Abstract]
[Full Text]
-
Szuplewski, S., Kottler, B., Terracol, R.
(2003). The Drosophila bZIP transcription factor Vrille is involved in hair and cell growth. Development
130: 3651-3662
[Abstract]
[Full Text]
-
Ozkurt, I. C., Tetradis, S.
(2003). Parathyroid Hormone-induced E4BP4/NFIL3 Down-regulates Transcription in Osteoblasts. J. Biol. Chem.
278: 26803-26809
[Abstract]
[Full Text]
-
Yu, Y.-L., Chiang, Y.-J., Yen, J. J. Y.
(2002). GATA Factors Are Essential for Transcription of the Survival Gene E4bp4 and the Viability Response of Interleukin-3 in Ba/F3 Hematopoietic Cells. J. Biol. Chem.
277: 27144-27153
[Abstract]
[Full Text]
-
Dijkers, P. F., Birkenkamp, K. U., Lam, E. W.-F., Thomas, N. S. B., Lammers, J.-W. J., Koenderman, L., Coffer, P. J.
(2002). FKHR-L1 can act as a critical effector of cell death induced by cytokine withdrawal: protein kinase B-enhanced cell survival through maintenance of mitochondrial integrity. J. Cell Biol.
156: 531-542
[Abstract]
[Full Text]
-
Bae, Y.-S., Kim, Y., Park, J. C., Suh, P.-G., Ryu, S. H.
(2002). The synthetic chemoattractant peptide, Trp-Lys-Tyr-Met-Val-D-Met, enhances monocyte survival via PKC-dependent Akt activation. J. Leukoc. Biol.
71: 329-338
[Abstract]
[Full Text]
-
Aldinucci, D., Poletto, D., Gloghini, A., Nanni, P., Degan, M., Perin, T., Ceolin, P., Rossi, F. M., Gattei, V., Carbone, A., Pinto, A.
(2002). Expression of Functional Interleukin-3 Receptors on Hodgkin and Reed-Sternberg Cells. Am. J. Pathol.
160: 585-596
[Abstract]
[Full Text]
-
Mitsui, S., Yamaguchi, S., Matsuo, T., Ishida, Y., Okamura, H.
(2001). Antagonistic role of E4BP4 and PAR proteins in the circadian oscillatory mechanism. Genes Dev.
15: 995-1006
[Abstract]
[Full Text]
-
Shinjyo, T., Kuribara, R., Inukai, T., Hosoi, H., Kinoshita, T., Miyajima, A., Houghton, P. J., Look, A. T., Ozawa, K., Inaba, T.
(2001). Downregulation of Bim, a Proapoptotic Relative of Bcl-2, Is a Pivotal Step in Cytokine-Initiated Survival Signaling in Murine Hematopoietic Progenitors. Mol. Cell. Biol.
21: 854-864
[Abstract]
[Full Text]
-
Rebollo, A., Martinez-A, C.
(1999). Ras Proteins: Recent Advances and New Functions. Blood
94: 2971-2980
[Full Text]
-
Wolfman, J. C., Wolfman, A.
(2000). Endogenous c-N-Ras Provides a Steady-state Anti-apoptotic Signal. J. Biol. Chem.
275: 19315-19323
[Abstract]
[Full Text]
-
Nishimura, Y., Tanaka, T.
(2001). Calcium-dependent Activation of Nuclear Factor Regulated by Interleukin 3/Adenovirus E4 Promoter-binding Protein Gene Expression by Calcineurin/Nuclear Factor of Activated T Cells and Calcium/Calmodulin-dependent Protein Kinase Signaling. J. Biol. Chem.
276: 19921-19928
[Abstract]
[Full Text]
-
Doi, M., Nakajima, Y., Okano, T., Fukada, Y.
(2001). Light-induced phase-delay of the chicken pineal circadian clock is associated with the induction of cE4bp4, a potential transcriptional repressor of cPer2 gene. Proc. Natl. Acad. Sci. USA
98: 8089-8094
[Abstract]
[Full Text]
-
Dijkers, P. F., Birkenkamp, K. U., Lam, E. W.-F., Thomas, N. S. B., Lammers, J.-W. J., Koenderman, L., Coffer, P. J.
(2002). FKHR-L1 can act as a critical effector of cell death induced by cytokine withdrawal: protein kinase B-enhanced cell survival through maintenance of mitochondrial integrity. J. Cell Biol.
156: 531-542
[Abstract]
[Full Text]